Paper Details

  1. Home
  2. Paper Details

Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.

Author: ChienMinchen, JockuschSteffen, JuJingyue, KalachikovSergey, KumarShiv, LiXiaoxu, MorozovaIrina, RussoJames J, TaoChuanjuan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Sofosbuvir is a drug that was originally developed to treat hepatitis C. This study found that Sofosbuvir can also inhibit the replication of SARS-CoV-2, the virus that causes COVID-19. The study suggests that Sofosbuvir could be used as a treatment for COVID-19, either alone or in combination with other drugs.
Paper Details　
Original Abstract of the Article :
SARS-CoV-2 is responsible for COVID-19, resulting in the largest pandemic in over a hundred years. After examining the molecular structures and activities of hepatitis C viral inhibitors and comparing hepatitis C virus and coronavirus replication, we previously postulated that the FDA-approved hepat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538426/

データ提供：米国国立医学図書館（NLM）

Sofosbuvir: A Potential Weapon in the Desert of COVID-19

The COVID-19 pandemic has created a vast and unforgiving desert of uncertainty, demanding relentless research efforts to find effective treatments. This study explores the potential of Sofosbuvir, an FDA-approved antiviral drug for hepatitis C, as a therapeutic option for COVID-19. The researchers analyzed the molecular structures and activities of Sofosbuvir and Remdesivir, another antiviral drug used for COVID-19, comparing their ability to resist removal by the SARS-CoV-2 exonuclease proofreader.

Sofosbuvir's Resilience: A Beacon of Hope in the Desert of COVID-19

The study found that Sofosbuvir-terminated RNA was significantly more resistant to removal by the SARS-CoV-2 exonuclease than Remdesivir-terminated RNA. This suggests that Sofosbuvir may have a longer-lasting antiviral effect, offering a potential advantage in the fight against COVID-19. This research adds to the growing body of evidence supporting the potential use of Sofosbuvir in COVID-19 treatment, providing a beacon of hope in the desert of this global pandemic.

Navigating the Desert of COVID-19: Seeking Effective Solutions

This research highlights the importance of exploring repurposed medications as potential treatments for COVID-19. As we navigate the ongoing challenges of this pandemic, we must continue seeking new and effective solutions.

Dr.Camel's Conclusion

This study provides compelling evidence for the potential of Sofosbuvir as a therapeutic option for COVID-19, offering a glimmer of hope in the desert of this ongoing pandemic. The study highlights the importance of exploring new and repurposed medications to combat this global health challenge.

Date :
  1. Date Completed 2020-10-27
  2. Date Revised 2021-10-06
Further Info :

Pubmed ID

33024223

DOI: Digital Object Identifier

PMC7538426

Related Literature

Article Analysis
・Effects of daclatasvir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.